Tufts researcher probes genes behind rare ocular sebaceous cancer
Bottom line
Sebaceous gland carcinoma is a rare, hard-to-diagnose eye cancer in people, and Tufts University pathologist Cornelia Peterson, DVM, PhD, is using comparative oncology to better understand what drives it. In a recent Tufts feature, Peterson described research centered on the MYC gene, comparing human tumors with canine Meibomian gland tumors and mouse models to identify molecular changes tied to malignancy and altered lipid metabolism. Her prior published work has already linked upregulated MYC expression and abnormal p53 patterns with canine Meibomian gland carcinomas, while related human studies have suggested MYC amplification alongside TP53 and RB1 mutations in ocular adnexal sebaceous carcinomas. (newswise.com)
Why it matters: For veterinary professionals, the work highlights how a common canine eyelid structure can inform a rare but aggressive human cancer. Most canine Meibomian gland tumors are benign, but carcinomas do occur, and Peterson’s research suggests dogs may share key molecular features with human sebaceous carcinoma. That gives veterinary pathology and ophthalmology a meaningful role in translational cancer research, especially as clinicians and diagnosticians work to distinguish benign from malignant sebaceous lesions and as comparative models help clarify which genetic changes may eventually support better diagnostics or targeted treatment strategies. (pubmed.ncbi.nlm.nih.gov)
What to watch: Watch for larger validation studies from Peterson’s group and collaborators, especially work testing whether MYC-driven pathways or lipid metabolism markers could improve diagnosis or open the door to new therapies in both veterinary and human ocular oncology. (vet.tufts.edu)
Key facts
- Research focus
- Sebaceous gland carcinoma
- Researcher
- Cornelia Peterson, DVM, PhD
- Institution
- Tufts University, Cummings School of Veterinary Medicine
- Comparative models
- Human tumors, canine Meibomian gland tumors, and mouse models
- Gene of interest
- MYC
- Canine findings
- MYC upregulation and aberrant p53 expression in canine Meibomian gland carcinomas
- Additional canine finding
- Reduced adipophilin expression in Meibomian gland neoplasms compared with normal glands
- Human findings
- TP53 and RB1 mutations, with suggested MYC amplification, in ocular adnexal sebaceous carcinomas
- Clinical context
- Most canine Meibomian gland tumors are benign, but carcinomas do occur
A Tufts University researcher is digging into the genetics of a rare eye cancer that can be devastating in human patients, and she’s doing it with help from dogs. Cornelia Peterson, DVM, PhD, an assistant professor of comparative pathobiology at Cummings School of Veterinary Medicine at Tufts, is studying sebaceous gland carcinoma, focusing on how the MYC gene may drive tumor behavior across human tissue, canine Meibomian gland tumors, and mouse models. (newswise.com)
The work sits at the intersection of ocular oncology and comparative pathology. Sebaceous carcinoma of the ocular adnexa is uncommon, which makes it harder to study and easier to miss clinically. In the Tufts feature, Peterson noted that rare cancers often lag in diagnostic progress because research attention and funding tend to flow toward more common diseases. Her program builds on earlier work at Johns Hopkins and Wisconsin, where she and collaborators characterized molecular changes in both human and canine sebaceous tumors. (newswise.com)
The canine angle is especially relevant for veterinary readers. In dogs, the Meibomian gland is the most common ocular adnexal structure to develop neoplasia, and most of those tumors are benign. Still, published work co-authored by Peterson found that canine Meibomian gland carcinomas showed MYC upregulation and aberrant p53 expression patterns, findings that may parallel features seen in human ocular adnexal sebaceous carcinoma. That same study also reported reduced adipophilin expression in Meibomian gland neoplasms compared with normal glands, pointing to altered lipid biology as another area of interest. (pubmed.ncbi.nlm.nih.gov)
The human side of the story reinforces why those comparisons matter. A next-generation sequencing study co-authored by Peterson identified common TP53 and RB1 mutations and suggested MYC amplification in ocular adnexal sebaceous carcinomas. More recently, Peterson also co-authored a case report describing ocular adnexal sebaceous carcinoma in a patient with Li-Fraumeni syndrome, underscoring the potential importance of genetic screening in unusual presentations and the broader role of tumor suppressor pathways in this disease. (pubmed.ncbi.nlm.nih.gov)
Outside experts have also described sebaceous carcinoma as an uncommon but potentially aggressive malignancy, particularly in periocular sites where delayed diagnosis can worsen outcomes. Evidence-based guidance in human medicine has emphasized complete margin-controlled surgery as the preferred treatment approach, and recent clinical literature has linked treatment delay with a greater risk of orbital exenteration in periocular disease. That context helps explain the urgency behind efforts to identify earlier molecular clues and more precise diagnostic markers. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this is a reminder that routine-seeming eyelid pathology can carry outsized research value. Although canine Meibomian tumors are often managed successfully and are not usually discussed in the same terms as aggressive human ocular cancers, comparative studies may reveal conserved pathways that sharpen diagnostic interpretation in both species. For pathologists, ophthalmologists, and oncologists, MYC, p53, and lipid metabolism are emerging as potentially important threads in sorting benign from malignant sebaceous lesions and in understanding how these tumors evolve. (pubmed.ncbi.nlm.nih.gov)
The work also fits a broader trend in translational veterinary medicine: using naturally occurring disease in animals to answer questions that are difficult to solve in rare human cancers. Peterson’s lab profile says she is building that program at Tufts with transduced human cell lines and transgenic mouse models, alongside comparative pathology expertise in canine tissue. That kind of platform could help move the field from descriptive pathology toward mechanism-driven biomarkers and, eventually, therapeutic hypotheses. (vet.tufts.edu)
What to watch: The next signals to watch are expanded cohort studies, mechanistic papers from Peterson’s lab, and any evidence that MYC- or lipid-related markers can improve diagnostic confidence or stratify risk. For veterinary clinicians, the practical near-term takeaway is less about an immediate change in care and more about recognizing that carefully characterized canine eyelid tumors may contribute to advances that matter well beyond the exam room. (newswise.com)